Faculty and staff members of the Maryland Center for Developmental Disabilities (MCDD) hope that the COVID-19 resources listed in this newsletter will provide useful information for you and for your family.
On December 8, 2021, the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) for Evusheld (formerly AZD7442) for emergency use in the U.S. for preexposure prevention of COVID-19. The EUA approval seems to provide long-awaited hope for adults and children 12 years of age and older who are moderately to severely immunocompromised and may not mount an adequate immune response, and for those who have been advised against the available COVID-19 vaccines due to severe allergies to components of the vaccine or a history of adverse reactions. A blog post, “Evusheld Offers Hope for Many, but Access Remains an Issue,” by Tracy Waller, Esq., MPH, MCDD staff attorney, was published by the Center for Dignity in Healthcare for People with Disabilities on January 7.
Maryland Developmental Disabilities Council: COVID-19 Vaccines—They Save Lives! (a plain language COVID-19 fact sheet)